Literature DB >> 11055897

Active intestinal chloride secretion in human carriers of cystic fibrosis mutations: an evaluation of the hypothesis that heterozygotes have subnormal active intestinal chloride secretion.

C Högenauer1, C A Santa Ana, J L Porter, M Millard, A Gelfand, R L Rosenblatt, C B Prestidge, J S Fordtran.   

Abstract

To explain the very high frequency of cystic fibrosis (CF) mutations in most populations of European descent, it has been proposed that CF heterozygotes have a survival advantage when infected with Vibrio cholerae or Escherichia coli, the toxins of which induce diarrhea by stimulation of active intestinal chloride secretion. Two assumptions underlie this hypothesis: (1) chloride conductance by the CF transmembrane conductance regulator (CFTR) is the rate-limiting step for active intestinal chloride secretion at all levels of expression, from approximately zero in patients with CF to normal levels in people who are not carriers of a mutation; and (2) heterozygotes have smaller amounts of functional intestinal CFTR than do people who are not carriers, and heterozygotes therefore secrete less chloride when exposed to secretagogues. The authors used an intestinal perfusion technique to measure in vivo basal and prostaglandin-stimulated jejunal chloride secretion in normal subjects, CF heterozygotes, and patients with CF. Patients with CF had essentially no active chloride secretion in the basal state, and secretion was not stimulated by a prostaglandin analogue. However, CF heterozygotes secreted chloride at the same rate as did people without a CF mutation. If heterozygotes are assumed to have less-than-normal intestinal CFTR function, these results mean that CFTR expression is not rate limiting for active chloride secretion in heterozygotes. The results do not support the theory that the very high frequency of CF mutations is due to a survival advantage that is conferred on heterozygotes who contract diarrheal illnesses mediated by intestinal hypersecretion of chloride.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11055897      PMCID: PMC1287919          DOI: 10.1086/316911

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  28 in total

1.  The cystic fibrosis heterozygote--advantage in surviving cholera?

Authors:  D M Rodman; S Zamudio
Journal:  Med Hypotheses       Date:  1991-11       Impact factor: 1.538

2.  A test of the heterozygote-advantage hypothesis in cystic fibrosis carriers.

Authors:  L B Jorde; G M Lathrop
Journal:  Am J Hum Genet       Date:  1988-06       Impact factor: 11.025

3.  Accounting for cystic fibrosis.

Authors:  P S Baxter; J Goldhill; J Hardcastle; P T Hardcastle; C J Taylor
Journal:  Nature       Date:  1988-09-15       Impact factor: 49.962

4.  Active chloride secretion in the normal human jejunum.

Authors:  G R Davis; C A Santa Ana; S Morawski; J S Fordtran
Journal:  J Clin Invest       Date:  1980-12       Impact factor: 14.808

5.  Complex allele [-102T>A+S549R(T>G)] is associated with milder forms of cystic fibrosis than allele S549R(T>G) alone.

Authors:  M C Romey; C Guittard; J P Chazalette; P Frossard; K P Dawson; M A Patton; T Casals; T Bazarbachi; E Girodon; G Rault; D Bozon; F Seguret; J Demaille; M Claustres
Journal:  Hum Genet       Date:  1999 Jul-Aug       Impact factor: 4.132

6.  Abnormal epithelial transport in cystic fibrosis jejunum.

Authors:  E V O'Loughlin; D M Hunt; K J Gaskin; D Stiel; I M Bruzuszcak; H C Martin; C Bambach; R Smith
Journal:  Am J Physiol       Date:  1991-05

7.  Effect of cholera toxin on the human jejunum.

Authors:  W Petritsch; A J Eherer; U Holzer-Petsche; T Hinterleitner; E Beubler; G J Krejs
Journal:  Gut       Date:  1992-09       Impact factor: 23.059

8.  The role of intraluminal junction potentials in the generation of the gastric potential difference in man.

Authors:  N W Read; J S Fordtran
Journal:  Gastroenterology       Date:  1979-05       Impact factor: 22.682

9.  Altered intestinal chloride transport in cystic fibrosis.

Authors:  H M Berschneider; M R Knowles; R G Azizkhan; R C Boucher; N A Tobey; R C Orlando; D W Powell
Journal:  FASEB J       Date:  1988-07       Impact factor: 5.191

10.  Intestinal fluid and electrolyte transport in human cholera.

Authors:  J G Banwell; N F Pierce; R C Mitra; K L Brigham; G J Caranasos; R I Keimowitz; D S Fedson; J Thomas; S L Gorbach; R B Sack; A Mondal
Journal:  J Clin Invest       Date:  1970-01       Impact factor: 14.808

View more
  11 in total

1.  Can a place of origin of the main cystic fibrosis mutations be identified?

Authors:  Eva Mateu; Francesc Calafell; Maria Dolors Ramos; Teresa Casals; Jaume Bertranpetit
Journal:  Am J Hum Genet       Date:  2001-11-16       Impact factor: 11.025

2.  Abnormal passive chloride absorption in cystic fibrosis jejunum functionally opposes the classic chloride secretory defect.

Authors:  Michael A Russo; Christoph Hogenauer; Stephen W Coates; Carol A Santa Ana; Jack L Porter; Randall L Rosenblatt; Michael Emmett; John S Fordtran
Journal:  J Clin Invest       Date:  2003-07       Impact factor: 14.808

3.  An ancient founder mutation in PROKR2 impairs human reproduction.

Authors:  Magdalena Avbelj Stefanija; Marc Jeanpierre; Gerasimos P Sykiotis; Jacques Young; Richard Quinton; Ana Paula Abreu; Lacey Plummer; Margaret G Au; Ravikumar Balasubramanian; Andrew A Dwyer; Jose C Florez; Timothy Cheetham; Simon H Pearce; Radhika Purushothaman; Albert Schinzel; Michel Pugeat; Elka E Jacobson-Dickman; Svetlana Ten; Ana Claudia Latronico; James F Gusella; Catherine Dode; William F Crowley; Nelly Pitteloud
Journal:  Hum Mol Genet       Date:  2012-07-05       Impact factor: 6.150

4.  Evaluating candidate agents of selective pressure for cystic fibrosis.

Authors:  Eric M Poolman; Alison P Galvani
Journal:  J R Soc Interface       Date:  2007-02-22       Impact factor: 4.118

5.  Recent origin and spread of a common Lithuanian mutation, G197del LDLR, causing familial hypercholesterolemia: positive selection is not always necessary to account for disease incidence among Ashkenazi Jews.

Authors:  R Durst; R Colombo; S Shpitzen; L B Avi; Y Friedlander; R Wexler; F J Raal; D A Marais; J C Defesche; M Y Mandelshtam; M J Kotze; E Leitersdorf; V Meiner
Journal:  Am J Hum Genet       Date:  2001-04-17       Impact factor: 11.025

6.  Origin and spread of the 1278insTATC mutation causing Tay-Sachs disease in Ashkenazi Jews: genetic drift as a robust and parsimonious hypothesis.

Authors:  Amos Frisch; Roberto Colombo; Elena Michaelovsky; Mazal Karpati; Boleslaw Goldman; Leah Peleg
Journal:  Hum Genet       Date:  2004-01-15       Impact factor: 4.132

7.  Elevated Mirc1/Mir17-92 cluster expression negatively regulates autophagy and CFTR (cystic fibrosis transmembrane conductance regulator) function in CF macrophages.

Authors:  Mia F Tazi; Duaa A Dakhlallah; Kyle Caution; Madelyn M Gerber; Sheng-Wei Chang; Hany Khalil; Benjamin T Kopp; Amr E Ahmed; Kathrin Krause; Ian Davis; Clay Marsh; Amy E Lovett-Racke; Larry S Schlesinger; Estelle Cormet-Boyaka; Amal O Amer
Journal:  Autophagy       Date:  2016-11       Impact factor: 16.016

8.  The great opportunity: Evolutionary applications to medicine and public health.

Authors:  Randolph M Nesse; Stephen C Stearns
Journal:  Evol Appl       Date:  2008-02       Impact factor: 5.183

9.  Common CFTR gene variants influence body composition and survival in rural Ghana.

Authors:  Maris Kuningas; David van Bodegom; Linda May; Johannes J Meij; P Eline Slagboom; Rudi G J Westendorp
Journal:  Hum Genet       Date:  2009-11-05       Impact factor: 4.132

10.  Intestinal current measurement versus nasal potential difference measurements for diagnosis of cystic fibrosis: a case-control study.

Authors:  Azadeh Bagheri-Hanson; Sebastian Nedwed; Claudia Rueckes-Nilges; Lutz Naehrlich
Journal:  BMC Pulm Med       Date:  2014-10-04       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.